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Available online 11 February 20167-(4-(Decanoyl)piperazin-1-yl)-ciproﬂoxacin, CipA, (1) which is an analogue of the antibiotic ciproﬂoxacin, and
its ruthenium(II) complex [Ru(η6-p-cymene)(CipA-H)Cl], (2) have been synthesised and the x-ray crystal struc-
tures of 1·1.3H2O·0.6CH3OH and 2·CH3OH·0.5H2O determined. The complex adopts a typical pseudo-
octahedral ‘piano-stool’ geometry, with Ru(II) π-bonded to the p-cymene ring and σ-bonded to a chloride and
two oxygen atoms of the chelated ﬂuoroquinolone ligand. The complex is highly cytotoxic in the low μM range
and is as potent as the clinical drug cisplatin against the human cancer cell lines A2780, A549, HCT116, and
PC3. It is also highly cytotoxic against cisplatin- and oxaliplatin-resistant cell lines suggesting a different mecha-
nism of action. The complex also retained low μM cytotoxicity against the human colon cancer cell line
HCT116p53 in which the tumour suppressor p53 had been knocked out, suggesting that the potent anti-
proliferative properties associated with this complex are independent of the status of p53 (in contrast to cisplat-
in). The complex also retained moderate anti-bacterial activity in two Escherichia coli, a laboratory strain and a
clinical isolate resistant to ﬁrst, second and third generation β-lactam antibiotics.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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The rational design and development of innovative anti-cancer
platinum drug candidates to overcome dose-limiting toxic side ef-
fects and resistance associated with drugs in clinical use have pro-
duced a wide range of possible chemotherapeutics. However, in the
50 or so years since the discovery of the anti-cancer properties of cis-
platin, it is surprising that none to date has been as successful as cis-
platin and its analogues carboplatin or oxaliplatin. Recent advances
in this ﬁeld have included the exploitation of various Pt drug delivery
vehicles [1] and the incorporation of metals other than Pt. In the
latter regard, ruthenium compounds have demonstrated much
promise with three Ru(III) complexes, NAMI-A (imidazolium trans-
[tetrachloro(dimethylsulfoxide)(1H-imidazole)ruthenate(III)]) [2,3],
KP1019 (indazolium trans-[tetrachlorobis(1H-indazole)-ruthenate(III)])
[4–6] and NKP-1339, the sodium salt analogue of KP1019 [4], alldler), cmarmion@rcsi.ie
. This is an open access article underundergoing clinical trials, Fig. 1. Ruthenium(III) complexes tend to be
less toxic, andmaymimic the behaviour of iron in the body, taking advan-
tage of transferrin-mediated delivery to cancer cells. Ruthenium(III) com-
plexes may also act as prodrugs, being reduced to and exerting their
biological effect as Ru(II) in the more reducing environment of tumour
cells.
Half-sandwich Ru(II)–arene complexes provide a versatile platform
for the design of anti-cancer complexes. For example, these complexes
can be rationally designed such that they incorporate various
biologically-relevant ligands or substituents, or ligands that serve to en-
hance the physicochemical properties of the complex, thus potentially
leading to innovative multi-functional drug candidates. One property
of potential value in the setting of cancer is anti-bacterial activity,
given the weakened ability of patients with cancer to ﬁght infection. A
multitude of Ru–arene-type complexes with promising anti-cancer ac-
tivity have been developed several of which target the nucleobases of
DNA, for example, [(Ru-p-cymene)(ethylenediamine)Cl]PF6 (RAED-C,
Fig. 1), which is as cytotoxic as cisplatin [7–9]. The structurally-related
anti-metastatic and anti-angiogenic agent [(Ru-p-cymene)(1,3,5-
triaza-7-phosphaadamantane)Cl2] (RAPTA-C, Fig. 1), in contrast,the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Chemical structures of NAMI-A, KP1019, RAED-C and RAPTA-C.
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mal histone proteins [9].
Ruthenium(II) arene complexes incorporating clinical drugs such as
ethacrynic acid (a gluthathione-S-transferase inhibitor) [10], tamoxifen
(a selective oestrogen receptor modulator) [11] and staurosporine (a
protein kinase inhibitor) [12] have been reported. Potential anti-
bacterial ligands include quinolones which inhibit bacterial DNA gyrase
and topoisomerase IV, enzymes thatmaintain the integrity of supercoiled
DNA during DNA replication and transcription. However, their cross-
reactivity with human class II topoisomerases has highlighted their po-
tential as anti-cancer agents [13]. The crystal structure of a topoisomer-
ase–DNA–quinolone (moxiﬂoxacin) derivative provides evidence that
the quinolone can bind the Mg2+ ion through O,O′-bidentate coordina-
tion with the remaining coordination sites occupied by aqua ligands
which in turn form hydrogen bonds with DNA nucleobases [14]. Turel
et al. have conjugated quinolones (oﬂoxacin [15], nalidixic acid [16] and
cinoxacin [16]) to the Ru–arene framework with the Ru(II) π-bonded to
a p-cymene (p-cym) ring and σ-bonded to the two oxygen atoms of the
chelated quinolonewith the remaining site occupied by a chloride ligand.
All three complexes, upon hydrolysis, rapidly and selectively form ad-
ducts with guanosine 5′-monophosphate via coordination to N7, thus
providing preliminary evidence that DNA may be a potential target. It
has also been suggested that electrostatic interactions and hydrogen
bonding may initially play a role in DNA recognition prior to guanosine
5′-monophosphate binding. Of the three complexes, only the oﬂoxacin
derivative demonstrated in vitro cytotoxicity and in only one of the cell
lines tested (CH1 with IC50 of 18 ± 7 μM) [16].
Fluoroquinolones are attractive for incorporation into metallodrugs
with anti-bacterial properties since they possess a much broader spec-
trum of anti-bacterial activity as well as an enhanced pharmacokinetic
proﬁle when compared to quinolones. The antibiotic ciproﬂoxacin
(Cip), a second generation orally or parentally administeredﬂuoroquin-
olone, was the drug of choice to treat victims infected by anthrax in
2001 [17]. Structural optimisation of this lead drug molecule has led
to derivatives with broad spectrum activities and minimal toxic side ef-
fects [18]. Metal complexes of Cip such as those of Co, Zn, Cd, Ni and Cu
have also been investigated as an alternative strategy to optimise its
therapeutic potential [19,20]. These complexes, in which Cip is bound
via O,O′-bidentate coordination, have comparable anti-bacterial activity
against several bacteria when compared to Cip itself. Interestingly, theFig. 2. Chemical structures of Cip, CipA (1complexes, in contrast to the ligand, are more bactericidal against sta-
tionary bacteria, a property which may be attractive for the treatment
of chronic or device-related infections (e.g. catheter infections) which
involve slowly metabolising bacteria in bioﬁlm mode [21]. Vieira et al.
recently reported a Pt–Cip derivative in which the antibiotic is com-
plexed via piperazineN,N′-coordination. A positive correlation between
lipophilicity, in vitro anti-tumour activity and rate of drug uptake was
observed [22]. Furthermore, Azema et al. reported a structure activity
study of 31 Cip derivatives investigating the correlation between lipo-
philicity and anti-tumour activity, with two lead candidates being iden-
tiﬁed, both demonstrating enhanced in vitro cytotoxicity in the low μM
range against a panel of tumour cell lines as compared to the parent Cip
[23]. Of the two, the 7-(4-(decanoyl)piperazin-1-yl) derivative CipA,
Fig. 2, was most potent. These derivatives, particularly CipA, have IC50
values in the low μM range (3–7 μM in 4 cell lines tested), but were also
non-toxic in an in vivo xenograft mouse model. While Cip is reported to
have anti-proliferative and anti-cancer effects itself, harnessing its anti-
bacterial activity in the cancer setting where signiﬁcant infection risks
are present due to immunosuppression, may augment its therapeutic ef-
fects. In the present work we attempt to combine into one drugmolecule
the anti-cancer properties of Ru–arene derivatives with the potent anti-
bacterial and anti-cancer properties of CipA, with a view to generating
novel multi-functional therapeutic agents to combat cancer.
Ruthenium(II) might bind to Cip ligands via O,O′- or N,N′-coordina-
tion. There is an example of a Ru(II)–piperazine complex in the litera-
ture with Ru(II) bound via N,N′-coordination, i.e. trans-dichloro-
piperazine-bis(ether-phosphine)ruthenium(II) [24], and another, [(η6-
p-cym)RuCl2(CH3NH(CH2)4NH)]PF6, in which the piperazine is bound
via one nitrogen [25]. It therefore seemed possible that we could selec-
tively and readily bind the 7-(4-(decanoyl)piperazin-1-yl) derivative of
Cip to Ru(II) via O,O′-coordination given thatN4 of the piperazine ring is
no longer free to coordinate.
Our rationale was that the complex, upon tumour cell entry, might
release CipA which can inhibit topoisomerases and/or bind DNA with
the concomitant release of the Ru–arene framework free also to bind
DNA. Release of chelating O,O′-ligands from Ru(II)–arene frameworks
has been reported in the literature [26]. Herein, we report the synthesis
and characterisation of CipA and Ru(η6-p-cym)(CipA-H)Cl, including
their X-ray crystal structures, as well as their anti-cancer and anti-
bacterial properties.) and [Ru(η6-p-cym)(CipA-H)Cl] (2).
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All starting materials, including Cip (N98%) and [Ru(η6-p-
cym)Cl2]2 (N98%), were used as received from Sigma Aldrich.
Propidium iodide (94%) and RNase were likewise purchased from
Sigma Aldrich.
1H, 13C and 19F NMR spectra were recorded using a Bruker DPX 400
spectrometer (at room temperature; 400MHz, 101MHz and 376MHz, re-
spectively). Coupling constants (J) are quoted in Hz. The splitting of the
proton resonances is labelled as s = singlet, d = doublet, t = triplet,
sept = septet, and m = multiplet. Chemical shifts (δ) are quoted in
parts per million using residual protons in the indicated solvents as inter-
nal standards. All NMRdata processingwas carried out usingMestReNova,
version 6.0.2-5475. Infrared spectra were recorded on a Bruker Tensor 27
spectrometer with KBr as a standard. IR spectra were analysed using
OPUS, version 5.0, with peak positions (ν) in cm−1. Mass spectrometry
was carried out with an Advion Expression Compact Mass Spectrometer:
10 μL of the samples was injected in 300 μL of methanol:water:formic
acid (90:9:1 v/v). Themass spectrometry data were acquired both in pos-
itive and negative ion modes. Microanalyses were carried out at the De-
partment of Chemistry, University College Dublin. Bacteria used for
testing were Escherichia coli (E. coli) strain ATCC25922, an antibiotic sus-
ceptible laboratory strain and E. coli clinical isolate CL2, isolated from a pa-
tient with a urinary tract infection. CL2 is an extended spectrum β-
lactamase (ESBL)-producer (resistant to 1st, 2nd and 3rd generation β-
lactam antibiotics), belonging to the internationally disseminated pan-
demic clone 025b:H4-ST-131 E. coli [27].Table 1
Crystal data and structure reﬁnement for 1·1.3H2O·0.6CH3OH and 2·CH3OH·0.5H2O.
1 2
Empirical formula C27.60H41FN3O5.90 C76H108Cl2F2N6O11Ru2
fw 528.23 1592.72
Crystal system Triclinic Triclinic
Space group Pī Pī
a (Å) 8.1142(4) 8.6844(4)
b (Å) 9.6285(4) 9.3426(4)
c (Å) 17.8315(8) 23.7743(12)
β (°) 100.003(2) 92.3359(15)
32.1. Synthesis of CipA (1)
Cip (3 g, 9 mmol) and triethylamine (1.38 mL, 9.9 mmol) were stirred
in dichloromethane (120 mL) at 273 K for 30 min. Decanoyl chloride
(4.67 mL, 22.5 mmol) was added dropwise. After stirring at 273 K for an
additional 45 min and then at room temperature for a further hour,
water (100mL)was added to themixture. The aqueous layerwas extract-
ed with dichloromethane (2 × 50 mL). Combined organics were washed
withwater (20mL) and dried over Na2SO4 and concentrated. The remain-
ing residuewas triturated in a copious amount of diethyl ether to generate
anoff-white solid, Fig. 3 (6.79mmol, 75.4%). 1HNMR(400MHz, dmso-d6):
δ=15.18 (s, 1H, –COOH), 8.67 (s, 1H, CH (6)), 7.93 (d, J=13.2Hz, 1H, CH
(13)), 7.58 (d, J= 7.5 Hz, 1H, CH (10)), 3.86–3.77 (m, 1H, CH (7)), 3.71–
3.62 (m, 4H, CH2 (14, 16)), 3.40–3.25 (m, 4H, CH2 (15, 17)), 2.36 (t, J=
7.5 Hz, 2H, CH2 (19)), 1.59–1.45 (m, 2H, CH2 (20)), 1.36–1.14 (m, 16H,
CH2 (8, 9, 21–26)), 0.85 (t, J = 6.8 Hz, 3H, CH3). 13C NMR (101 MHz,
dmso-d6): δ = 176.31 (C3), 170.80 (C18), 165.84 (C1), 154.14 (C12),
147.98 (C6), 144.89 (C11), 139.09 (C5), 118.74 (C4), 111.06 (C13),
110.83 (C2), 106.65 (C10), 49.69 (C14), 49.23 (C16), 44.56 (C15), 40.57
(C17), 35.84 (C7), 32.18 (C19), 31.26 (C20), 28.90 (C21–C23), 28.72
(C24), 24.74 (C25), 22.07 (C26), 13.91 (C27), 7.55 (C8, C9). 19F NMR
(376MHz, dmso-d6): δ=−121.77 (dd, J=13.2, 7.5Hz). ESI-MS (positive
mode;MeOH)m/z485.6 [M], 486.6 [MH]+. IR selected bands (cm−1, KBr):
2920, 1885, 1721, 1630, 1472, 1340, 1300, 1260, 1024, 949, 886 cm−1.
Anal. Calcd for C27H36FN3O4: C, 66.78; H, 7.47; N, 8.65; F, 3.91. Found: C,
66.70; H, 7.48; N, 8.70; F, 3.76.Fig. 3. Chemical structure of CipA (1).2.2. Synthesis of [Ru(η6-p-cym)(CipA-H)Cl] (2)
CipA (0.13 mmol, 63.5 mg) was dissolved in chloroform/methanol
(1/1) (20 mL). The mixture was left stirring at 333 K until all the CipA
dissolved. Afterwards, NaOMe (0.13 mmol, 25% wt. in MeOH, 7.1 mg,
28 μL) was added dropwise. After an additional 15 min of stirring at
room temperature, the solution was added dropwise to [Ru(η6-p-
cym)Cl2]2 (0.065 mmol, 40 mg) dissolved in chloroform/methanol (1/
1) (50 mL) and the reaction mixture was reﬂuxed for 48 h. The NaCl
produced was removed by ﬁltration through Celite. The solvent was re-
moved in vacuo. A few drops of dichloromethane and n-hexane (15mL)
were added to the light orangewaxy residue to give a light yellow solid.
The solid was ﬁltered off and dried under vacuum to afford a yellow
ﬂaky solid (0.072 mmol, 55.4%). 1H NMR (400 MHz, dmso-d6): δ =
8.59 (s, 1H, CH (6)), 8.03 (d, J = 13.5 Hz, 1H, CH (13)), 7.48 (d, J =
7.5 Hz, 1H, CH (10)), 5.74 (t, J = 6.6 Hz, 2H, Ar-H cym), 5.43 (t, J =
6.6 Hz, 2H, Ar-H cym), 3.74–3.67 (m, 5H, CH (7), CH2 (14, 16)), 3.25
(s, 4H, CH2 (15, 17)), 2.90 (sept, 1H, Ar-CH(CH3)2 cym), 2.35 (t, J =
7.3 Hz, 2H, CH2 (19)), 2.17 (s, 3H, Ar-CH3 cym), 1.51 (s, 2H, CH2 (20)),
1.31 (d, J = 6.9 Hz, 6H, Ar-CH(CH3)2), 1.27–1.01 (m, 16H, CH2 (8, 9,
21–26)), 0.85 (t, J= 6.4 Hz, 3H, CH3 (27)). 13C NMR (101 MHz, dmso-
d6): δ = 170.79 (C3, C18), 165.39 (C1), 151.82 (C12), 148.45 (C6),
144.50 (C11), 137.28 (C5), 119.53 (C4), 112.42 (C13), 111.72–110.87
(C2, C10), 97.99 (Ar-C cym), 96.15 (Ar-C cym), 82.34 (Ar-CH cym),
82.05 (Ar-CH cym), 77.95 (Ar-CH cym), 77.82 (Ar-CH cym), 49.81
(C14), 49.30 (C16), 44.57 (C15), 40.56 (C17), 35.51 (C7), 32.18 (C19),
31.26 (C20), 30.40 (Ar-CH(CH3)2), 28.90 (C21–C23), 28.72 (C24),
24.76 (C25), 22.03 (C26, Ar-CH(CH3)2), 17.58 (Ar-CH3), 13.93
(C27), 7.54 (C8, C9). 19F NMR (376 MHz, dmso-d6): δ = −122.21
(dd, J = 13.5, 7.4 Hz). ESI-MS (positive mode; MeOH) m/z 755.2
[M], 719.91 [M−Cl]+. IR selected bands (cm−1, KBr): 2925, 1651,
1631, 1552, 1519, 1481, 1298, 1261, 1021, 949, 885 cm−1. Anal.
Calcd for C37H49ClFN3O4Ru.0.5H2O: C, 58.14; H, 6.59; N, 5.34; Cl,
4.64; F, 2.49. Found: C, 57.96; H, 6.13; N, 5.37; Cl, 4.37; F, 2.24.
2.3. Structure analysis
Crystallographic data for CipA and [Ru(η6-p-cym)(CipA-H)Cl] were
collected on a Bruker APEX DUO with Mo Kα radiation (λ= 1.54178
and 0.71073 Å) using a MiTeGen micromount and at 100(2) K (Oxford
Cobra Cryosystem). Bruker APEX2 [28] software was used to collect
and reduce data, determine the space group, solve and reﬁne the struc-
ture. Absorption corrections were applied using SADABS [29]. FinalV (Å ) 90.839(2) 99.2449(15)
T (K) 96.521(3) 91.4334(15)
Z 2 1
ρ (mg/cm3) 1.288 1.391
μ (mm−1) 0.781 0.534
Total reﬂns 35,732 74,715
Indep. reﬂns 4937 11,051
R(int) 0.0869 0.0572
S 1.038 1.097
R1
a [I N 2σ(I)] 0.0591 0.045
wR2 [I N 2σ(I)] 0.1573 0.0931
CCDC number 1429461 1429462
a R1 = Σ||Fo|− |Fc||/Σ|Fo|, wR2 = [Σw(Fo2− Fc2)2/Σw(Fo2)2]1/2.
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atoms were reﬁned anisotropically. For reﬁnement details see supple-
mentary crystallographic data. See Table 1 for crystal data and structure
reﬁnement parameters. CCDC 1429461 and 1429462 contain the sup-
plementary crystallographic data for this paper.
2.4. Cell culture
A2780, A549, HCT116, and PC3 cells of ovarian, lung, colon and
prostate origin, together with their derived cell lines A2780Cis (cis-
platin (CDDP) resistant), HCT116Ox (oxaliplatin (OXA) resistant)
and HCT116p53 (p53 knocked out) were obtained from the European
Collection of Cell Cultures (ECACC) and grown in Roswell ParkMemori-
al Institutemedium (RPMI-1640), Dulbecco'smodiﬁed Eagle'smedium,
or McCoy's Modiﬁed 5A medium supplemented with 10% v/v of foetal
calf serum, 1% v/v of 2 mM glutamine and 1% v/v penicillin/streptomy-
cin. All cells were grown as adherent monolayers at 310 K in a 5%
CO2 humidiﬁed atmosphere and passaged at approximately 70–80%
conﬂuency.
2.5. In vitro growth inhibition assay
Brieﬂy, 96-well plates were used to seed 5000 cells per well. The
plates were left to pre-incubate in drug-free medium at 310 K for 48 h
before adding different concentrations of the compounds to be tested.
A drug exposure period of 24 h was allowed. After this, supernatants
were removed by suction and each well was washed with phosphate-
buffered saline (PBS). A further 72 hwas allowed for the cells to recover
in drug-free medium at 310 K. The sulforhodamine B (SRB) assay was
used to determine cell viability [31]. IC50 values, as the concentration
which caused 50% of cell death, were determined as duplicates of tripli-
cate in two independent sets of experiments and their standard devia-
tions were calculated. Cells exposed to cisplatin or oxaliplatin as well as
untreated cells were used as positive and negative controls respectively.
2.6. Cell cycle analysis
A549 lung cancer cells were seeded in a 6-well plate using 1.0 × 106
cells per well. They were pre-incubated in drug-free medium at 310 K
for 24 h, after which [Ru(η6-p-cym)(CipA-H)Cl] was added using
equipotent concentrations equal to IC50 and 2× IC50. After 24 h of
drug exposure, supernatants were removed by suction and cells were
washedwith PBS. Finally, cells were harvested using trypsin. DNA stain-
ing was achieved by re-suspending the cell pellets in PBS containing
propidium iodide and RNAse A. Cell pellets were re-suspended in PBS
before being analysed by ﬂow cytometry using themaximumexcitation
of propidium iodide-bound DNA at 536 nm, and its emission at 617 nm.
Data were processed using Flowjo software. These experiments used
untreated cells as negative controls, and cisplatin-exposed cells as pos-
itive controls. All experiments were carried out in triplicate. Although
only selected histograms are shown, full numerical data and statistical
analysis can be found in the Supporting Information.
2.7. Induction of apoptosis
Flow cytometry analysis of apoptotic populations was carried out
using the Annexin V-FITC Apoptosis Detection Kit (Sigma Aldrich) ac-
cording to the manufacturer's instructions. Brieﬂy, A549 lung cancer
cells were seeded in 6-well plates (1.0 × 106 cells per well), pre-
incubated for 24 h in drug-free media at 310 K, after which they were
exposed to [Ru(η6-p-cym)(CipA-H)Cl] for a further 24 h (equipotent
concentrations equal to IC50 and 2× IC50). Cells were harvested using
trypsin and stained using propidium iodide/Annexin V-FITC. After stain-
ing in the dark, cell pelletswere analysed in a BectonDickinson FACScan
Flow Cytometer. For positive-apoptosis controls A549 cells were ex-
posed for 2 h to staurosporine (1 μg/mL) or for 24 h to cisplatin. Cellsfor apoptosis studies were used with no previous ﬁxing procedure as
to avoid non-speciﬁc binding of the Annexin V-FITC conjugate. Negative
controls included untreated cells. These experiments were carried out
in triplicate, although only selected dot plots are shown, full numerical
data and statistical analysis can be found in the Supporting Information.
2.8. Statistical analysis
In all cases, independent two-sample t-testswith unequal variances,
Welch's tests, were carried out to establish statistical signiﬁcance of the
variations (p b 0.01 for **, and p b 0.05 for *).
2.9. Bactericidal assays
A modiﬁcation of a previously described method was used [32].
Brieﬂy, bacteria were grown overnight at 310 K on Mueller-Hinton
(MH) agar. Suspensions were prepared from isolated colonies to the
density of a 0.5 McFarland standard (bioMérieux, Ireland) using a den-
sitometer (Densichek, bioMérieux). The suspension was further diluted
1/10 inMH broth. Tested agents were dissolved in 10% DMSO in 10mM
potassium phosphate buffer (pH 6.8). Assays of 100 μL volumes were
prepared in microcentrifuge tubes and contained 0 to 500 μM tested
agents, 10% (vol/vol) E. coli (ca. 1.5–105 CFU/mL), and 10mMpotassium
phosphate buffer, pH 6.8. Assay mixtures were incubated at 310 K and
120 rpm in a shaking incubator (Gallenkamp, United Kingdom) for 1 h
and then diluted 1/10 with 0.95% (wt/vol) NaCl. After vortex-mixing
for 30 s, 10–100 μL aliquots were spread onto MH agar and incubated
overnight at 310 K. Percentage killing activity was calculated from via-
ble counts (CFU/mL) from assays containing tested agents compared
to control assays not containing tested agents.
3. Results and discussion
The synthesis of CipA was carried out following a previously reported
procedure with one slight modiﬁcation [23]. Treatment of commercially
available Cipwith decanoyl chloride in the presence of triethylamine gen-
erated a white solid in good yield and excellent purity. In contrast with
the reported method where silica gel chromatography (eluent: CH2Cl2–
MeOH 1–2%) was used to achieve the desired purity of CipA, trituration
with diethyl ether served this purpose based on differences in solubilities
between CipA and unreacted starting materials. Suitable crystals of CipA
for X-ray diffraction analysis were obtained from a methanol solution
upon slow evaporation at room temperature.
Treatment of [Ru(η6-p-cym)Cl2]2 with CipA in the presence of sodi-
ummethoxide afforded [Ru(η6-p-cym)(CipA-H)Cl] in good yield and ex-
cellent purity. [Ru(η6-p-cym)(CipA-H)Cl] was isolated as a yellow ﬂaky
solid which was both air and moisture stable. Needle-like light orange
crystals of [Ru(η6-p-cym)(CipA-H)Cl]·CH3OH·0.5H2O, suitable for X-
ray analysis, were obtained by slow evaporation of a dichloromethane
and n-hexane mixture. To assess the likelihood of intracellular CipA re-
lease, the stability of complex 2 under aqueous conditions was moni-
tored by 1H NMR spectroscopy, the details of which are provided in
Supporting Information. The release of CipA from 2 was observed in
under an hour.
3.1. Solid state structures
The complex [Ru(η6-p-cym)(CipA-H)Cl], Fig. 4 adopts a typical
pseudo-octahedral ‘piano-stool’ geometry, with Ru(II) π-bonded to
the p-cymene ring and σ-bonded to a chloride and two oxygen atoms
of the chelated ﬂuoroquinolone ligand. When comparing the crystal
structure of CipA, Fig. 4 to that of the complex, we can see a slight
lengthening of the d(C1–O2) carbonyl bond from 1.213(3) to
1.243(3) Å, indicative of delocalisation, Table 2. The expected shorten-
ing of the bond between d(C1–O1) in [Ru(η6-p-cym)(CipA-H)Cl] is
also observed. The distances between Ru(II) and the exocyclic carbonyl
Fig. 4. (Top)Molecular structure of 1with atomic displacement parameters shown at 50% probability. Only one conformation of the disordered chain is shown for clarity. Hydrogen atoms
and solventmolecules (1.3 H2O in twopositions and 0.6 CH3OH) omitted for clarity also. (Bottom)Molecular structure of 2with atomic displacement parameters shown at 50% probability.
Hydrogen atoms and disordered solvent (CH3OH in two positions; 0.5 H2O) omitted for clarity.
214 Z. Ude et al. / Journal of Inorganic Biochemistry 160 (2016) 210–217and carboxylate oxygens are 2.0897(17) Å and 2.0875(17) Å, respec-
tively, consistent with literature reports. The Ru–Cl bond length is
2.4214(6) Å, within the expected range. The metal to ring centroid dis-
tance d(Ru1–cymenecentroid) is 1.6396(2) Å, again consistent with liter-
ature reports. The O1–Ru–O3 and O–Ru–Cl angles are between 83.53°
and 86.76°. This is within the same range as previously reported for
other similar Ru–cymene complexes [33]. CipA co-crystallised with a
water/methanol mixture (one fully occupied water molecule and par-
tially occupied water andmethanol molecules). The water forms strong
hydrogen bonds with the carbonyl oxygens (d(O3–Owater), d(O4–
Owater) of 2.863(3) and 2.721(2) Å respectively). On the other hand,
[Ru(η6-p-cym)(CipA-H)Cl] co-crystallised with a mixture of water and
methanol (one molecule of methanol disordered over two positions
and a half occupied water molecule), despite the complex being recrys-
tallised from a mixture of dichloromethane:hexane. The molecule of
water forms hydrogen bonds with the chloride on Ru(II) (d(Cl–Owater)
of 3.310(4) Å) and the carbonyl oxygen (d(O2–Owater) of 2.715(4) Å).
One molecule of methanol forms a hydrogen bond with the chloride
(d(Cl–Omethanol) of 3.211(4) Å) and the other molecule of methanolTable 2
Selected bond lengths and angles for 1·1.3H2O·0.6CH3OH and 2·CH3OH·0.5H2O.
1 2
Bond lengths/Å C1–O1 1.337(3) 1.279(3)
C1–O2 1.213(3) 1.243(3)
C3–O3 1.274(2) 1.279(3)
Ru–O1 – 2.0875(17)
Ru–O3 – 2.0897(17)
Ru–Cl – 2.4214(6)
Ru–cymenecentroid – 1.6396(2)
Angle/° O1–Ru–O3 – 86.10(7)
O1–Ru–Cl – 86.76(5)
O3–Ru–Cl – 83.53(3)hydrogen bonds with the uncoordinated decanoyl carbonyl oxygen
(d(O4–Cmethanol) of 2.927(7) Å).
3.2. Anti-proliferative activity
The anti-proliferative activity of Cip, CipA and [Ru(η6-p-
cym)(CipA-H)Cl] towards a variety of human cancer cell lines of ovari-
an, lung, prostate and colon origin was investigated and compared to
that of cisplatin and oxaliplatin which were used as positive controls,
Table 3. Interestingly, in all cases [Ru(η6-p-cym)(CipA-H)Cl] resulted
in signiﬁcantly enhanced cytotoxicity as compared to its organic chelat-
ing ligand, CipA and the corresponding biologically active precursor,
Cip. The metal complex [Ru(η6-p-cym)(CipA-H)Cl] was highly cytotoxic
in all cell lines tested with potencies in the low μM range (0.25 to
6.2 μM), comparable to the activity of cisplatin. The chelating ligand
CipA, in contrast, was cytotoxic in A2780 ovarian, A549 lung and PC3
prostate cancer lines, but to a much lesser extent with values ranging
between 7 and 15 μM. Cip was inactive in all cell lines tested.
In the A2780 human ovarian cell line, there is an order of magnitude
difference in potency between CipA and [Ru(η6-p-cym)(CipA-H)Cl]. In-
terestingly, the ligand CipA loses activity in the cisplatin-resistant cell
line A2780Cis with an IC50 value N50 μM, in stark contrast to the Ru
complex which shows a resistance factor of only 1.65 (calculated as
the ratio between the IC50 values in the resistant and IC50 in the parental
line). It has been proposed that the underlying resistance associated
with A2780Cis involves a two-fold more efﬁcient efﬂux and a conse-
quent reduction in cellular accumulation as compared to the parental
A2780 aswell as an increase inDNA-repairmechanisms [34]. Themech-
anism of action of [Ru(η6-p-cym)(CipA-H)Cl] must therefore differ from
cisplatin given that it demonstrates low μM cytotoxicity in both the
cisplatin-sensitive and -resistant A2780 cell lines. Another striking re-
sult is observed for the HCT116 colon cancer cell line. Cip and CipA are
inactive, with IC50 values N100 μM, while [Ru(η6-p-cym)(CipA-H)Cl]
Table 3
Cytotoxicities of Cip, CipA (1), [Ru(η6-p-cym)(CipA-H)Cl] (2), cisplatin (CDDP) and oxaliplatin (OXA) against A2780, A2780Cis, A549, HCT116, HCT116Ox, HCT116p53 and PC3 cell lines.
Compound IC50/μM
A2780 A2780Cis A549 HCT116 HCT116Ox HCT116p53 PC3
Cip N50 N75 N50 N100 N100 N100 N50
1 11.2 ± 0.4 N50 7.0 ± 0.3 N100 N100 N100 15.6 ± 0.3
2 1.027 ± 0.004 1.7 ± 0.1 0.25 ± 0.04 1.33 ± 0.07 1.93 ± 0.03 6.2 ± 0.8 1.46 ± 0.08
CDDP 1.2 ± 0.2 11.5 ± 0.3 3.3 ± 0.1 5.1 ± 0.3 N/D 36.7 ± 0.3 N/D
OXA N/D N/D N/D 3.99 ± 0.08 32.2 ± 0.5 N100 N/D
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in the oxaliplatin-resistant derived line HCT116Ox (resistant factor =
1.45). Oxaliplatin resistance associated with HCT116Ox has been linked
to apoptosis regulator BAX expression resulting in an increase in
gluthathione-S-transferase levels; this increase facilitates cellular de-
toxiﬁcation and reduction in levels of Pt–DNA adducts as a consequence
of an increase in DNA repair [35]. Again, the mechanism of action of
[Ru(η6-p-cym)(CipA-H)Cl] must therefore differ from oxaliplatin given
that it demonstrates low μM cytotoxicity in both the oxaliplatin-
sensitive and -resistant HCT116 cell lines. Given that [Ru(η6-p-
cym)(CipA-H)Cl] has been shown to be highly cytotoxic against these
two resistant cell lines would therefore suggest that cellular processes
such as reduced accumulation, increased efﬂux or enhanced DNA repair
mechanisms, all of which have been implicated in the resistance associ-
ated with cisplatin and oxaliplatin, do not appear to affect the anti-
proliferative activity of [Ru(η6-p-cym)(CipA-H)Cl].
In order to further elucidate the mechanism of action of [Ru(η6-p-
cym)(CipA-H)Cl], we sought to investigate the involvement of oncogene
p53 in its activity. Tumour suppressor p53, known as the guardian of the
genome, is involved in facilitating DNA repair before DNA replication
[36,37]. Modiﬁcations in its expression before or after chemotherapy
can lead to transcriptional activation of p21 and p73which results in ap-
optosis. Most importantly, there is a close connection between cell cycle
arrest and the expression of this tumour suppressor. This is particularly
true in colorectal cancers in which p53 is found to be mutated in more
than 50% of clinical cases and the status of p53 can inﬂuence directly
the sensitivity to the Pt drugs, cisplatin and especially oxaliplatin. Inactive
p53 oncogene has been linked to poor patient prognosis and treatment
failure [38]. We therefore investigated the involvement of oncogene p53
in the activity of [Ru(η6-p-cym)(CipA-H)Cl] in the colorectal cell line
HCT116 and compared it to that of oxaliplatin. For this we determined
the anti-proliferative activity of tested compounds in a derived cell line
which had the tumour suppressor p53 knocked out. Our data show that
[Ru(η6-p-cym)(CipA-H)Cl] retains activity in the HCT116p53 mutated
cell line with an IC50 value of 6.2 ± 0.8 μM (resistance factor of 4.6)
when compared to oxaliplatin (resistant factor N 25). This suggests that
the status of p53 is not highly relevant for the anti-cancer activity ofFig. 5. Cell cycle analysis of A549 cells exposed to [Ru(η6-p-cym)(CipA-H)Cl at equipotent conce
reading propidium iodide ﬂuorescence. Right: bar chart showing the percentage cell populatio[Ru(η6-p-cym)(CipA-H)Cl] and that the mechanism of action of this
novel drug may not involve the activation of this oncogene.
3.3. Flow cytometry
Based on the anti-proliferative activity results, further analysis of the
cellular behaviour of [Ru(η6-p-cym)(CipA-H)Cl] was performed in the
A549 lung cancer cell line, where it showed sub-μM potency. Its effect
on the cell cycle proﬁle of cells exposed to equipotent concentrations
of [Ru(η6-p-cym)(CipA-H)Cl] equal to 1× and 2× the IC50 valueswas in-
vestigated. The induction of apoptosis under similar conditionswas also
investigated. In both cases, the data for [Ru(η6-p-cym)(CipA-H)Cl] were
compared to the results obtained when the same cell line was exposed
to cisplatin at IC50 concentrations.
Cell cycle proﬁles can be readily obtained by ﬂow cytometry using
propidium iodide staining, as it binds quantitatively to nuclear DNA of
ﬁxed cells. Fluorescencemeasured in the FL2 red channel can be related
to the number of DNA copies present in the single cell suspension
analysed, so populations in theG1, G2/Mand S phases can bequantiﬁed.
Two concentrations of [Ru(η6-p-cym)(CipA-H)Cl] were used and the
populations in the three cell cycle phases to those of an untreated neg-
ative control and a cisplatin-exposed positive control were compared,
Fig. 5. As expected, the negative controls showedmost of the population
in a G1 phase (72.6%) with similar values for the S and G2/M phases
(13.7 and 13.5% respectively). In comparison, cisplatin-exposed cells
show a sharp increase in the S phase population (up to 29.5%) while the
G1 decreases to 54% and the G2/M remains approximately stable at
14.8%. This clear S-phase arrest caused by the platinum-based drug is
very well established in the literature and it is a consequence of a mech-
anism of action that involves coordinative binding to the double helix
and subsequent structural modiﬁcation of the cellular DNA [39,40].
Cells treated with [Ru(η6-p-cym)(CipA-H)Cl] showed a statistically
signiﬁcant change in the population distribution, with the G1 phase re-
ducing to 59 and 56% when exposed to 1× and 2× IC50 concentrations,
respectively, Fig. 5 and Supporting Information. In consequence, the S
and G2/M phases increase. It is however not possible to establish if
there is a signiﬁcant arrest in any of these two particular phases as thentrations equal to 1× and 2× IC50. Left: Flow cytometry histograms of the FL2 red channel
n present in each of the cell cycle phases, (p b 0.01 for **, and p b 0.05 for *).
Table 4
Bactericidal activity of test agents against E. coli.
Compound % bactericidal activity*
E. coli ESBL-E. coli
Strain ATCC25922 CL2
Cip 83.4 ± 9.9a 91.7 ± 2.9a
84.4 ± 8.0b 94.4 ± 2.3b
99.4 ± 0.4c 94.4 ± 1.7c
1 98.5 ± 0.8a 72.8 ± 15.9a
99.7 ± 0.1b 75.0 ± 14.8b
99.6 ± 0.3c 80.0 ± 11.0c
2 38.9 ± 12.9a 19.9 ± 7.0a
51.2 ± 12.2b 30.3 ± 4.0b
48.9 ± 12.9c 52.1 ± 7.4c
*Data representmean± SEM of the results of 3 separate determinations carried out in du-
plicate over the concentration range (a— 200 μM, b— 400 μM, c— 500 μM). Aﬁxed number
of bacteria (1× 105 CFU/mL)were exposed to the agent for 1 h and% killingwas calculated
compared to controls which were not exposed to the agent.
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the highest concentration (21 and 20% for S and G2/M phases, respec-
tively). It is also possible that the mechanism of action of [Ru(η6-p-
cym)(CipA-H)Cl] involves DNA interaction and a subsequent S phase ar-
rest, aswell as a disruption of themitoticmachinerywhich could lead to
a G2/M arrest. Importantly, this S/G2/M arrest has also been observed
previously in transitional bladder cell carcinoma (HTB9 cell line) treated
with Cip, possibly due to modulation of key cell cycle regulatory genes
and the downregulation of initial trigger for antigen-presenting cell ac-
tivation in mitosis, Cyclin B/cdc2-kinase, which is also necessary for
degradation of mitotic cyclins [41].
Apoptosis, programmed cell death, is a cellular process often in-
volved in the anti-proliferative activity ofmetal-based complexes. Its in-
duction after drug exposure can be followed by ﬂow cytometry analysis
using a combination of Annexin V and propidium iodide staining. Viable
cells should exhibit low ﬂuorescence when observed in a FL1-green and
FL2-red dot plot, while early apoptotic cells should be located in a
quadrant with high Annexin V and low propidium iodide ﬂuorescence.
In this case, cells have lost the symmetry of the phospholipidmembrane
and allowAnnexin binding only. In late stages of apoptosis, the integrity
of the membrane is lost and cells become permeant to the nuclear
intercalator, which would locate them in a ﬂow cytometry quadrant
with high Annexin and high propidium iodide ﬂuorescence. The last
quadrant, which corresponds to low Annexin V but high propidium io-
dide ﬂuorescence, shows non-viable cells.
Untreated controls used as comparison, as expected, showed the
majority of the population in the quadrant with low ﬂuorescence for
both stains.Meanwhile cells exposed to cisplatin, used as a positive con-
trol, showed a statistically signiﬁcant increase in the population of non-
viable cells (high propidium iodide) and late apoptotic cells (high ﬂuo-
rescence reading in both channels), Fig. 6 and Supporting Information.
Cells exposed to [Ru(η6-p-cym)(CipA-H)Cl], in contrast, had a statisti-
cally relevant increase of cells in the three quadrants that have high ﬂuo-
rescence, particularly in those that have high readings for propidium
iodide as a nuclear staining, Fig. 6. At the highest concentration tested,
the population of viable cells (lowAnnexin V, low propidium iodide) var-
ied from 97 to 81% while the late apoptotic population (high Annexin V,
high propidium iodide) increased from 0.4 to 6.5%. Interestingly, the pop-
ulation that showed only high propidium iodide ﬂuorescence increased
from 0.5 to 7%, Fig. 6. These studies indicate that [Ru(η6-p-cym)(CipA-
H)Cl] begins to induce apoptosis after 24 h of drug exposure, butmost im-
portantly that this may not be the only cell death process occurring. As
mentioned before, the anti-cancer activity of Cip has been investigated
against HTB9 bladder carcinoma cells. In this case, Cip induces signiﬁcant
apoptosis but only after 72 h of drug exposure. At this point there is pro-
teolytic cleavage of poly (ADP-ribose) polymerase (proteins involved in a
number of cellular processes including programmed cell death and DNAFig. 6. Induction of apoptosis of A549 cells exposed to [Ru(η6-p-cym)(CipA-H)Cl] at equipotent
Annexin V ﬂuorescence and FL2 red propidium iodide ﬂuorescence. Right: bar chart showing th
p b 0.05 for *).repair) and a signiﬁcant alteration of the ratio between BAX and one of
the proteins that regulates cell death, Bcl-2. At 24 h of drug exposure, it
seems that BAX could be translocated into the mitochondria, but its con-
centration is not high enough to inducemitochondrial membrane poten-
tial changes and activation of the caspase cascadewhichwill in turn result
in apoptosis [41]. The slow induction of apoptosis observed does not rule
out the involvement of parallel mechanisms of cell death, in fact, metal-
based complexes are often multi-targeted and can have multiple mecha-
nisms of action [42,43].
Cip has also been investigated for the treatment of pancreatic can-
cers. Here, the ﬂuoroquinolone induces apoptosis after triggering both
intrinsic and extrinsic pathways with activation of caspases 8, 9, and 3
(some of the cysteine proteases that play essential roles in apoptosis).
It has even been suggested that pathways such as the extracellular
signal-regulated kinase (ERK) pathway could be involved in its mecha-
nism of action. Interestingly, it is also known that cisplatin induces
apoptosis after activation of this pathway. Saini et al. studied the combi-
nation of Cip and cisplatin as a 48 h co-administration. They attributed
the observed increase in the anti-proliferative activity to the double
activation of ERK1/2 [44]. In light of the above, further studies will be
required to understand more fully the mechanism of action of [Ru(η6-
p-cym)(CipA-H)Cl].
3.4. Bactericidal activity
The bactericidal activity of Cip, CipA and [Ru(η6-p-cym)(CipA-H)Cl]
is summarised in Table 4. The Ru–cymene starting material, [Ru(η6-p-
cym)Cl2]2, showed no activity against E. coli over the concentrationconcentrations equal to 1× and 2× IC50. Left: Flow cytometry dot plot showing FL1 Green
e percentage cell population present in each of the dot plot quadrants, (p b 0.01 for **, and
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killing activity in the range 72.8–99.7% against antibiotic susceptible and
ESBL-E. coli over the concentration range 50–500 μM. [Ru(η6-p-
cym)(CipA-H)Cl] had moderate activity against both strains of E. coli
which appeared dose dependent for ESBL-E. coli. The highest extent of
killing by the complex was 49% and 52% for fully susceptible E. coli
and ESBL-E. coli, respectively (at 500 μM; 1 h incubation). The reduced
potency observed compared to CipA may reﬂect reduced uptake of the
complex across the Gram-negative cell envelope or inefﬁcient release
of CipA from the complex when internalised. However, these data indi-
cate that up to half of the potency of Cip is retained when complexed to
Ru, at least under the conditions tested. The retention of this property
when combined with its potent cytotoxic effects in three cancer cell
lines is encouraging and can form the basis for further investigation of
its anti-bacterial activity particularly in the context of cancer. Such
studies might involve particularly antibiotic-resistant strains that are
clinically signiﬁcant in the context of cancer and cause healthcare-
associated infections in the immunocompromised including central ve-
nous or peripheral line infections. It should be noted however that the
concentrations of [Ru(η6-p-cym)(CipA-H)Cl] at which in vitro bacteri-
cidal activity was observed are an order of magnitude greater than the
concentration range at which anti-proliferative activity was found. Fur-
ther investigation of the bactericidal activity under assay conditions that
more closely mimic the in vivo environment of infection, may reduce
this differential.4. Conclusion
A half-sandwich, ‘piano-stool’ organo-ruthenium(II) arene
complex [Ru(η6-p-cym)(CipA-H)Cl] which incorporates 7-(4-
(decanoyl)piperazin-1-yl)-ciproﬂoxacin as an O,O′-chelated ligand
has been synthesised, and the x-ray crystal structures of both the com-
plex and the ciproﬂoxacin analogue have been determined. The com-
plex is highly cytotoxic in the low μM range and is as potent as the
clinical drug cisplatin against the human cancer cell lines A2780,
A549, HCT116, and PC3 of ovarian, lung, colon and prostate origin, as
well as cisplatin- and oxaliplatin-resistant cell lines suggesting a differ-
ent mechanism of action. The complex also retained low μM cytotoxic-
ity against the human colon cancer cell line HCT116p53 in which the
tumour suppressor p53 had been knocked out, suggesting that the po-
tent anti-proliferative properties associatedwith this complex are inde-
pendent of the status of p53 (in contrast to cisplatin). The complex also
retained moderate and dose-dependent anti-bacterial activity in both
E. coli, one of which was a clinical isolate resistant to ﬁrst, second and
third generation β-lactam antibiotics. In conclusion, we have success-
fully employed a multi-functional approach to combine into one drug
molecule the anti-cancer properties of Ru(II)–arene derivatives with
the anti-cancer and anti-bacterial properties of CipA.Acknowledgements
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